Hematuria differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 17: Line 17:
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
| colspan="9" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations'''
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="3" rowspan="5" |'''Gold standard'''
! rowspan="5" |'''Gold standard'''
|-
|-
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
Line 52: Line 52:
| style="background: #F5F5F5; padding: 5px;" | '''Biopsy:'''  
| style="background: #F5F5F5; padding: 5px;" | '''Biopsy:'''  
IgA deposited in a diffuse granular patte-rn in the mesangium
IgA deposited in a diffuse granular patte-rn in the mesangium
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
*  
*  
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Alport syndrome|Hereditary nephritis (Alport syndrome)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Alport syndrome|Hereditary nephritis (Alport syndrome)]]
Line 75: Line 74:
| style="background: #F5F5F5; padding: 5px;" |'''Biopsy:'''
| style="background: #F5F5F5; padding: 5px;" |'''Biopsy:'''
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of typ-e IV collagen
* Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of typ-e IV collagen
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Genetic analysis
* Genetic analysis
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Poststreptococcal glomerulonephritis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Poststreptococcal glomerulonephritis]]
Line 101: Line 99:
* Immunoglobulin G and C3 in a diffuse granular pattern  
* Immunoglobulin G and C3 in a diffuse granular pattern  
* Starr-y sky pattern
* Starr-y sky pattern
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Focal segmental glomerulosclerosis|Focal segmental glomerular sclerosis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Focal segmental glomerulosclerosis|Focal segmental glomerular sclerosis]]
Line 127: Line 124:
* Segmental solidification in the perihilar region and  peripheral areas, specially the tubular pole
* Segmental solidification in the perihilar region and  peripheral areas, specially the tubular pole
* Coarsely granular deposits -of IgM and C3
* Coarsely granular deposits -of IgM and C3
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Rapidly progressive glomerulonephritis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Rapidly progressive glomerulonephritis]]
Line 154: Line 150:
| style="background: #F5F5F5; padding: 5px;" | Biopsy:
| style="background: #F5F5F5; padding: 5px;" | Biopsy:
* Diffuse, proliferative, necrotizing glomerulonephritis with cresc-ent formation
* Diffuse, proliferative, necrotizing glomerulonephritis with cresc-ent formation
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lupus nephritis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lupus nephritis]]
Line 177: Line 172:
| style="background: #F5F5F5; padding: 5px;" | Biopsy,  
| style="background: #F5F5F5; padding: 5px;" | Biopsy,  
* Different pathologies, [[Lupus nephritis|CLICK HERE]] for more- information.
* Different pathologies, [[Lupus nephritis|CLICK HERE]] for more- information.
| colspan="2" style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" | -
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fabry's disease|Fabry disease]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fabry's disease|Fabry disease]]
Line 194: Line 188:
* Proteinuria
* Proteinuria
| style="background: #F5F5F5; padding: 5px;" | Biopsy
| style="background: #F5F5F5; padding: 5px;" | Biopsy
| colspan="2" style="background: #F5F5F5; padding: 5px;" | Biopsy
| style="background: #F5F5F5; padding: 5px;" | Biopsy
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
Line 210: Line 204:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tubulointerstitial diseases of the kidney|Tubulointerstitial diseases]]
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Tubulointerstitial diseases of the kidney|Tubulointerstitial diseases]]
Line 230: Line 223:
* [[Eosinophils]] are present, often in large numbers.  
* [[Eosinophils]] are present, often in large numbers.  
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephrolithiasis]]
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephrolithiasis]]
Line 253: Line 245:
* Abdominal CT scan without contrast
* Abdominal CT scan without contrast
| style="background: #F5F5F5; padding: 5px;" |Abdominal Ct scan without contrast
| style="background: #F5F5F5; padding: 5px;" |Abdominal Ct scan without contrast
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |–
|-
|-
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Reflux nephropathy|Reflux nephropathy (hydronephrosis)]]
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Reflux nephropathy|Reflux nephropathy (hydronephrosis)]]
Line 279: Line 269:
* Biopsy: Kidney scar
* Biopsy: Kidney scar
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malignancy]]
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Malignancy]]
Line 301: Line 289:
* The histological pattern of renal cell [[carcinoma]] depends whether it is [[Papillary|papillary,]] [[chromophobe]] or [[collecting duct]] renal cell carcinoma.
* The histological pattern of renal cell [[carcinoma]] depends whether it is [[Papillary|papillary,]] [[chromophobe]] or [[collecting duct]] renal cell carcinoma.
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephroblastoma]] ([[Wilms' tumor|Wilms tumor]])
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Nephroblastoma]] ([[Wilms' tumor|Wilms tumor]])
Line 332: Line 319:
**[[Fibrous connective tissue|Fibrous tissue.]]
**[[Fibrous connective tissue|Fibrous tissue.]]
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Bladder cancer]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Bladder cancer]]
Line 349: Line 335:
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostate cancer]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostate cancer]]
Line 366: Line 351:
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |Ultrasound, CT scan, Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
Line 382: Line 366:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Familial|Familial diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Familial|Familial diseases]]
Line 422: Line 405:
* Microcysts
* Microcysts
| style="background: #F5F5F5; padding: 5px;" |Ultrasound
| style="background: #F5F5F5; padding: 5px;" |Ultrasound
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Vascular anomaly|Vascular diseases]]
| rowspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Vascular anomaly|Vascular diseases]]
Line 447: Line 429:
* Venography
* Venography
| style="background: #F5F5F5; padding: 5px;" |'''Renal venography:''' Gold standard
| style="background: #F5F5F5; padding: 5px;" |'''Renal venography:''' Gold standard
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Granulomatosis with polyangiitis|Wegner's granulomatosis polyangiitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Granulomatosis with polyangiitis|Wegner's granulomatosis polyangiitis]]
Line 477: Line 458:
* [[Degranulation]] of [[neutrophils]].
* [[Degranulation]] of [[neutrophils]].
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Henoch-Schönlein purpura]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Henoch-Schönlein purpura]]
Line 500: Line 480:
IgA deposited in a diffuse granular pattern in the mesangium
IgA deposited in a diffuse granular pattern in the mesangium
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy, and clinical syndrome
| style="background: #F5F5F5; padding: 5px;" |Renal biopsy, and clinical syndrome
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Disease
Line 516: Line 495:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urinary system|Lower urinary tract diseases]]
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urinary system|Lower urinary tract diseases]]
Line 545: Line 523:
* Biopsy to rule out cancer
* Biopsy to rule out cancer
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |Biopsy
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urolithiasis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urolithiasis]]
Line 552: Line 529:
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 563: Line 539:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Interstitial cystitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Interstitial cystitis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 578: Line 553:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Radiogenic|Radiogenic cystitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Radiogenic|Radiogenic cystitis]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 594: Line 568:
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Systemic diseases]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Systemic diseases]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemophilia|Coagulopathy (hemophilia)]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hemophilia|Coagulopathy (hemophilia)]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 609: Line 582:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sickle cell anemia]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sickle cell anemia]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 624: Line 596:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Abdominal aortic aneurysm]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Abdominal aortic aneurysm]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 639: Line 610:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphomas]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Lymphomas]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 654: Line 624:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Multiple myeloma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Multiple myeloma]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 682: Line 651:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Diagnosis method
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Gold standard
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious disease|Infectious diseases]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Infectious disease|Infectious diseases]]
Line 706: Line 674:
* [[Abscess|Abscesses]] may not be present
* [[Abscess|Abscesses]] may not be present
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Cystitis]]
Line 730: Line 697:
* Also help to detect the presence of a [[tumor]] or a [[Stone massage|stone]].
* Also help to detect the presence of a [[tumor]] or a [[Stone massage|stone]].
| style="background: #F5F5F5; padding: 5px;" |Urine culture
| style="background: #F5F5F5; padding: 5px;" |Urine culture
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostatitis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Prostatitis]]
Line 753: Line 719:
* Edema of the [[prostate gland]] with diffuse enlargement,.
* Edema of the [[prostate gland]] with diffuse enlargement,.
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urethritis]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urethritis]]
Line 774: Line 739:
* Diffuse, circumferential urothelial wall thickening and contrast-enhancement
* Diffuse, circumferential urothelial wall thickening and contrast-enhancement
* Periureteric or perinephric fat stranding.
* Periureteric or perinephric fat stranding.
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
Line 786: Line 750:
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 794: Line 757:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Urogenital|Urogenital trauma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Inserted [[bladder]] or [[Ureteral disease|ureteral catheters]]
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 16:59, 1 February 2019

Hematuria Microchapters

Home

Patient Information

Overview

Definition

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hematuria from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hematuria differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hematuria differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hematuria differential diagnosis

CDC on Hematuria differential diagnosis

Hematuria differential diagnosis in the news

Blogs on Hematuria differential diagnosis

Directions to Hospitals Treating Hematuria

Risk calculators and risk factors for Hematuria differential diagnosis

Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Omer Kamal, M.D.[1], Venkata Sivakrishna Kumar Pulivarthi M.B.B.S [2]

Overview

Gross hematuria(GH) must be distinguished from pigmenturia, which may be due to endogenous sources (e.g., bilirubin, myoglobin,and porphyrins), foods ingested (e.g., beets and rhubarb), drugs (e.g., phenazopyridine), and simple dehydration. This distinction can be made easily by urinalysis with microscopy. Notably, myoglobinuria and other factors can cause false-positive chemical tests for hemoglobin, so urine microscopy is required to confirm the diagnosis of hematuria. GH also must be distinguished from vaginal bleeding in women, which usually can be achieved by obtaining a careful menstrual history, collecting the specimen when the patient is not having menstrual or gynecologic bleeding, or, if necessary, obtaining a catheterized specimen. GH may also be detected by the presence of blood spotting on the undergarments of incontinent patients. After ruling out vaginal bleeding and mimics of hematuria, a urologic source must be suspected.

Differential Diagnosis

Hematuria should be differentiated from other disease which mimic hematuria especially hemoglobinuria and myoglobinuria which are dipstick positive but negative for microscopy.

Hematuria differential diagnosis

Differentiating the diseases that can cause hematuria:

Diseases Clinical manifestations Para-clinical findings Gold standard
Symptoms Physical examina
Lab Findings Diagnosi
Low back pain Fever Nausea/

Vomiting

Urinary symptoms Hypertension Pitting edema Other
Dysuria Frequency Oliguria
Glomerular diseases IgA nephropathy (Berger nephropathy) + - - - + + + - - Biopsy:

IgA deposited in a diffuse granular patte-rn in the mesangium

Biopsy
Hereditary nephritis (Alport syndrome) - - - - - - + -
  • Cataract
  • Hearing loss
Biopsy:
  • Monoclonal antibodies directed against alpha-3 (IV), alpha-4 (IV), and alpha-5 (IV) chains of typ-e IV collagen
  • Genetic analysis
Poststreptococcal glomerulonephritis +/- + - - + + + +
  • Edema
  • Anemia
  • Increased Blood Pressure
  • Urine samples for protein and blood

Biopsy

  • Irregularly thin and attenuated GBM
  • Splitting of GBM
  • Scarring
  • Immunoglobulin G and C3 in a diffuse granular pattern
  • Starr-y sky pattern
Biopsy
Focal segmental glomerular sclerosis - - - - - - + +
  • Nephrotic syndrome
  • ESRD
  • Pleural effusion
  • Ascites
  • Abdominal pain
  • Urinalysis reveals large amounts of protein, along with hyaline and broad waxy casts
  • Hepatitis B or C infection
  • Antineutrophil cytoplasmic antibody titers, serum protein electrophoresis
Biopsy
  • Segmental solidification in the perihilar region and peripheral areas, specially the tubular pole
  • Coarsely granular deposits -of IgM and C3
Biopsy
Rapidly progressive glomerulonephritis + + + - - - + -
  • Abdominal pain
  • Painful cutaneous nodules
  • Migratory polyarthropathy
  • Sinusitis
  • Cough
  • Hemoptysis.
  • Low iron
  • Eosinophilia
  • Increased serum creatinine level
  • Eleated LDH and CPK
  • Proteinuria
Biopsy:
  • Diffuse, proliferative, necrotizing glomerulonephritis with cresc-ent formation
Biopsy
Lupus nephritis - + - - - - + +
  • Foamy dark urine
  • Weight gain
Biopsy,
  • Different pathologies, CLICK HERE for more- information.
Biopsy
Fabry disease - - - - - - + + -
  • Hematuria
  • Proteinuria
Biopsy Biopsy
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard
Tubulointerstitial diseases + + + Rash Biopsy:
  • Edema and infiltration by mononuclear cells, (principally lymphocytes)
  • Eosinophils are present, often in large numbers.
Renal biopsy
Nephrolithiasis + ± + ± ± ±
  • Radiating pain to groin
  • Hydronephrosis +/- in sonography
  • Abdominal CT scan without contrast
Abdominal Ct scan without contrast
Reflux nephropathy (hydronephrosis) + + - - - - - +
  • Elevated WBC count
  • Elevated BUN
  • Hyperkalemia
  • Ultrasound: Hydronephrosis +/-
  • Biopsy: Kidney scar
Malignancy Renal cell carcinoma (RCC) - - - - - - ± ±
  • Flank mass
  • Anemia
  • Hematuria
Nephroblastoma (Wilms tumor) - - - - - - - -
  • Abdominal pain

Biopsy:

Biopsy
Bladder cancer - - - - ± ± - - Suprapubic pain Ultrasound, CT scan, Biopsy Biopsy
Prostate cancer ± - - - ± ± - - - Ultrasound, CT scan, Biopsy Biopsy
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard
Familial diseases Polycystic kidney disease + - - - - - + + Ultrasound:
  • Unilateral or bilateral cysts

CT:

  • Hyperdense appearance,
  • Septations
  • Calcifications

Genetic testing demonstrates:

  • Frame insertions/deletions
  • Non-canonical splice site alterations
  • Combined missense changes

Biopsy:

  • Interstitial fibrosis
  • Tubular atrophy
  • Thickening and lamellation of tubular basement membranes
  • Microcysts
Ultrasound
Vascular diseases Renal vein thrombosis + + + - - - - -
  • Asymptomatic
  • Abdominal pain
  • Acute in onset
  • Elevation in serum lactate dehydrogenase
  • Cholesterol levels for hypercholesterolemia
  • Albumin levels for hypoalbuminemia
  • Serum complement levels
  • Ultrasound,
  • Venography
Renal venography: Gold standard
Wegner's granulomatosis polyangiitis - - - - - +/- + +
  • URTI
  • CNS involvement
  • Ophthalmic involvement
  • Proteniuria
  • Microscopic hematuria
  • RBC casts
CT chest:

Biopsy:

Biopsy
Henoch-Schönlein purpura - - - - - +/- +/- +
  • Abdominal pain
  • Rash
  • Hematuria
  • Proteniuria
  • Microscopic hematuria
  • RBC casts
Biopsy:

IgA deposited in a diffuse granular pattern in the mesangium

Renal biopsy, and clinical syndrome
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard
Lower urinary tract diseases Benign prostatic hyperplasia +/- - - + + - - -
  • Nocturia
  • Other voiding symptoms
    • Slow urinary stream
    • Splitting or spraying of the urinary stream
    • Intermittent urinary stream
    • Hesitancy
    • Straining to void
    • Terminal dribbling
  • Urinalysis to rule out UTI
  • Elevated BUN/Cr
  • High PSA values
  • Urine cytology to screen for bladder cancer
  • Biopsy to rule out cancer
Biopsy
Urolithiasis + +/- + +
Interstitial cystitis
Radiogenic cystitis
Systemic diseases Coagulopathy (hemophilia)
Sickle cell anemia
Abdominal aortic aneurysm
Lymphomas
Multiple myeloma
Disease Low back pain Fever Nausea/

Vomiting

Dysuria Frequency Oliguria Hypertension Pitting edema Other Lab Findings Diagnosis method Gold standard
Infectious diseases Pyelonephritis + + + + + + - - CT and ultrasound:
  • Enlarged kidneys
  • Round swollen kidneys
  • Hypodense appearance
  • Abscesses may not be present
-
Cystitis - - - + + + - -
  • Ultrasound:
  • Presence of a gas in the bladder wall.
  • Also help to detect the presence of a tumor or a stone.
Urine culture
Prostatitis - + - + + + - -
  • Body aches
Ultrasound:
  • Focal hypoechoic region located in the peripheral part of the prostate

CT scan:

-
Urethritis -/- + - + + + - -
  • Urethral discharge

CT scan:

  • Diffuse, circumferential urothelial wall thickening and contrast-enhancement
  • Periureteric or perinephric fat stranding.
Epididymitis -/+ + + - - - - -
Urogenital trauma Inserted bladder or ureteral catheters

References

  1. Hartman DS, Sanders RC (April 1982). "Wilms' tumor versus neuroblastoma: usefulness of ultrasound in differentiation". J Ultrasound Med. 1 (3): 117–22. PMID 6152936.
  2. De Campo JF (1986). "Ultrasound of Wilms' tumor". Pediatr Radiol. 16 (1): 21–4. PMID 3003660.
  3. Cahan LD (1985). "Failure of encephalo-duro-arterio-synangiosis procedure in moyamoya disease". Pediatr Neurosci. 12 (1): 58–62. PMID 4080660.

Template:WH Template:WS